BiotechTube
Home/Kallyope/Shirly Pinto, Ph.D.
SP

Shirly Pinto, Ph.D.

Chief Scientific Officer

Kallyope

Therapeutic Areas

MigraineMetabolic Disorders

Kallyope Pipeline

DrugIndicationPhase
Elismetrep (K-304)Acute Treatment of MigrainePhase 2
K-554Metabolic Disorders / ObesityPreclinical
Undisclosed Metabolic ProgramMetabolic DisordersDiscovery

Leadership Team at Kallyope

JG
Jay Galeota
CEO & President
PF
Patrick Flanigan
Chief Financial Officer
BL
Brett Lauring, M.D., Ph.D.
Chief Medical Officer
FH
Franz Humer, Ph.D.
Chair, Board of Directors
View full Kallyope profile